The effects of suppressing inflammation by tofacitinib may simultaneously improve glycaemic parameters and inflammatory markers in rheumatoid arthritis patients with comorbid type 2 diabetes: a proof‑of‑concept, open, prospective, clinical study
https://pubmed.ncbi.nlm.nih.gov/38178250/
Tofacitinib treatment resulted in a significant simultaneous improvement of both metabolic and inflammatory parameters in RA patients with T2D. Due to increasing evidence for a link between RA, insulin resistance and T2D Di Muzio et al. investigated if consecutively recruited RA patients on tofacitinib therapy showed improvement in HOMA2-IR values over 6 months.
Progressive improvement in insulin sensitivity and glycated haemoglobin were also observed. No major or life-threatening AEs or were recorded, and all side effects were completely reversed by discontinuation of tofacitinib.
Keywords:
